【摘要】 目的:探讨重组人脑利钠肽(rhBNP)-沙库巴曲缬沙坦序贯疗法用于急性心力衰竭(AHF)治疗的临床价值。方法:选取2019年6月—2021年1月我院就诊的AHF患者90例开展研究,按照随机分组法将其分为观察组和对照组,每组45例。对照组给予rhBNP治疗,观察组则采取rhBNP-沙库巴曲缬沙坦序贯疗法治疗,比较两组NT-proBNP及心功能、结构指标[包括心率、左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室后壁厚度(LVPW)];记录两组患者治疗疗效和不良反应发生情况。结果:观察组治疗总有效率为95.56%,高于对照组82.22%,差异有统计学意义(P<0.05);观察组NT-proBNP和LVEF数值高于对照组,差异有统计学意义(P<0.05),而两组心率、LVEDD、LVPW数值比较,差异无统计学意义(P>0.05);观察组不良反应发生率为4.44%,低于对照组11.11%,但差异无统计学意义(P>0.05)。结论:采取rhBNP-沙库巴曲缬沙坦序贯疗法治疗AHF的效果显著,可有效改善急性心力衰竭患者心功能,减少不良反应发生情况,安全性更高,值得推广应用。更多还原

【Abstract】 Objective: To investigate the clinical value of recombinant human brain natriuretic peptide(rhBNP)-sakubatro valsartan sequential therapy in the treatment of acute heart failure(AHF). Methods: A total of 90 patients with AHF admitted to our hospital from June 2019 to January 2021 were selected and divided into observation group and control group according to random grouping method, with 45 cases in each group. The control group was treated with rhBNP, while the observation group was treated with rhBNP-sakubatra valsartan sequential therapy. NT-proBNP and cardiac function, structural indexes [including heart rate, left ventricular ejection fraction(LVEF), left ventricular end diastolic diameter(LVEDD), left ventricular posterior wall thickness(LVPW)] were compared between the two groups. The therapeutic efficacy and adverse reactions of the two groups were recorded. Results: The total effective rate of the observation group was 95.56%, which was higher than 82.22% of the control group, and the difference was statistically significant(P<0.05). NT-proBNP and LVEF in the observation group were higher than those in the control group, and the difference was statistically significant(P<0.05),there was no significant difference in heart rate, LVEDD and LVPW between the two groups(P>0.05). The incidence of adverse reactions in the observation group was 4.44%, which was lower than 11.11% in the control group, but the difference was not statistically significant(P>0.05). Conclusion: TU The effect of rhBNP-sakubatril valsartan sequential therapy in the treatment of AHF is significant, which can effectively improve the cardiac function of patients with acute heart failure, reduce the occurrence of adverse reactions, and has higher safety. It is worthy of popularization and application.更多还原